FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
Separation of Irinotecan Hydrochloride and its Chiral Impurity per USP Monograph under Allowable Adjustments
Irinotecan hydrochloride is a chemotherapeutic agent classified as a DNA topoisomerase I inhibitor. Irinotecan is frequently administered alongside other drugs for the treatment of metastatic colon and rectal cancer, and occasionally for small cell lung cancer. The USP monograph specifies the use of an L40 column (4.6-mm × 25-cm; 10-µm), which is a Cellulose tris (3,5 dimethylphenylcarbamate) polymer column. In this technical note we demonstrate the utilization of Lux™- Cellulose-1, (5 µm 150 x 4.6 mm) as an alternative column for the separation of Irinotecan Hydrochloride and its chiral impurity per the allowable adjustments outlined in USP General Chapter <621>. The system Suitability per USP monograph is resolution NLT 2.5 between Irinotecan related compound D and Irinotecan, a percent relative standard deviation (%RSD) of NMT 5.0%, for standard solution and the Irinotecan related compound D peak should be visible for the sensitivity solution. All the system suitability requirements have been met by this column.
Separation of Irinotecan Hydrochloride and its Chiral Impurity per USP Monograph under Allowable Adjustments
Irinotecan hydrochloride is a chemotherapeutic agent classified as a DNA topoisomerase I inhibitor. Irinotecan is frequently administered alongside other drugs for the treatment of metastatic colon and rectal cancer, and occasionally for small cell lung cancer. The USP monograph specifies the use of an L40 column (4.6-mm × 25-cm; 10-µm), which is a Cellulose tris (3,5 dimethylphenylcarbamate) polymer column. In this technical note we demonstrate the utilization of Lux™- Cellulose-1, (5 µm 150 x 4.6 mm) as an alternative column for the separation of Irinotecan Hydrochloride and its chiral impurity per the allowable adjustments outlined in USP General Chapter <621>. The system Suitability per USP monograph is resolution NLT 2.5 between Irinotecan related compound D and Irinotecan, a percent relative standard deviation (%RSD) of NMT 5.0%, for standard solution and the Irinotecan related compound D peak should be visible for the sensitivity solution. All the system suitability requirements have been met by this column.
Separation of Irinotecan Hydrochloride and its Chiral Impurity per USP Monograph under Allowable Adjustments
Irinotecan hydrochloride is a chemotherapeutic agent classified as a DNA topoisomerase I inhibitor. Irinotecan is frequently administered alongside other drugs for the treatment of metastatic colon and rectal cancer, and occasionally for small cell lung cancer. The USP monograph specifies the use of an L40 column (4.6-mm × 25-cm; 10-µm), which is a Cellulose tris (3,5 dimethylphenylcarbamate) polymer column. In this technical note we demonstrate the utilization of Lux™- Cellulose-1, (5 µm 150 x 4.6 mm) as an alternative column for the separation of Irinotecan Hydrochloride and its chiral impurity per the allowable adjustments outlined in USP General Chapter <621>. The system Suitability per USP monograph is resolution NLT 2.5 between Irinotecan related compound D and Irinotecan, a percent relative standard deviation (%RSD) of NMT 5.0%, for standard solution and the Irinotecan related compound D peak should be visible for the sensitivity solution. All the system suitability requirements have been met by this column.